Spanish RNAi drug developer Sylentis said this week that it has been authorized to manufacture research drugs as a pharmaceutical laboratory by the Spanish Agency for Medicines and Healthcare Products.
"Authorization of Sylentis as a pharmaceutical laboratory is further recognition of the hard work and enthusiasm invested" in the company by parent firm Zeltia, Veronica Ruz, technical director of the lab, said in a statement.